Personalis, Inc.

PSNL

US71535D1063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
1.61 ^USD	-3.01%		+6.62%	-23.33%

Jul. 11	Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests	MT
Jul. 11	Myriad Genetics, Inc. and Personalis, Inc. Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing	CI

Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

January 04, 2023 at 04:01 pm EST

Personalis, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. For the quarter, the company expects revenue of approximately $16.7 million.

Latest news about Personalis, Inc.

Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests	Jul. 11	MT
Myriad Genetics, Inc. and Personalis, Inc. Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing	Jul. 11	CI
Transcript : Personalis, Inc. - Special Call	Jun. 21
Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $19.5M, vs. Street Est of $18.4M	May. 08	MT
Personalis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Personalis, Inc. Provides Earnings Guidance for the Second Quarter of 2024	May. 08	CI
Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024	May. 08	CI
Lake Street Starts Personalis With Buy Rating, $4 Price Target	Apr. 30	MT
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	Mar. 26	CI
Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	Feb. 29	MT
Transcript : Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M	Feb. 28	MT
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 28	CI
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Personalis to Offer ClearNote's Epigenomic Platform in Partnership	Jan. 30	MT
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	Jan. 30	CI
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay	Jan. 16	CI
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 05	CI
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test	Nov. 28	MT
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing	Nov. 28	CI
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	Nov. 16	MT
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	Nov. 16	CI
Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating	Nov. 08	MT

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Personalis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.61 USD

Average target price

4.6 USD

Spread / Average Target

+185.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PERSONALIS, INC.	-23.33%	83.62M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.32%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research

Personalis, Inc.

Equities

PSNL

US71535D1063

Biotechnology & Medical Research

Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Latest news about Personalis, Inc.

Chart Personalis, Inc.

Company Profile

Income Statement Evolution

Ratings for Personalis, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research